3 Biotech Stocks With Massive Upside to Buy Before August Starts
The article highlights three biotech stocks for August and later catalysts. Regeneron (REGN) is cited as down about 11% YTD despite Q1 2026 revenue of $3.605B and non-GAAP EPS $9.47, plus a $3.0B buyback. Moderna (MRNA) is noted for a Q1 2026 revenue jump to $389M and an Aug. 5 FDA PDUFA for flu vaccine mRNA-1010. Viking Therapeutics (VKTX) is pre-revenue with Phase 3 obesity trials and a $92.58 analyst target.
How this was made
The 30-second read
Why it matters
Traders can use the dated catalysts (Aug. 5 FDA PDUFA for MRNA, August action date for REGN’s garetosmab BLA, and Q3 2026 Phase 3 initiation for VKTX’s oral VK2735) to plan event-driven positioning and hedging around volatility windows.
Market read
Provides a catalyst calendar-style setup for three biotech names, but it is not a single-company breaking news item beyond the cited scheduled milestones and previously reported financials.
What to watch
EYLEA biosimilar launch timing, manufacturing disruption margin pressure, and the possibility that regulatory outcomes are already priced in could reduce realized upside versus the article’s target-driven narrative.
Background
The piece is a three-stock biotech “basket” organized by risk, anchored to upcoming FDA/clinical milestones and supported by cited recent financial results and capital return for REGN.
Ticker impact
Article highlights Regeneron’s Q1 2026 beats, $3.0B buyback authorization, and catalysts like garetosmab BLA with an August 2026 action date.
Moderate positive bias into August catalysts, with downside risk if EYLEA decline and margin disruption persist.
The piece provides specific Q1 financials, buyback size, and dated catalysts, but it is still a multi-name “buy before August” promotional structure rather than a fresh disclosure.
Article cites an FDA PDUFA date of Aug. 5 for Moderna’s seasonal flu vaccine mRNA-1010 as a concrete near-term catalyst.
High event sensitivity around Aug. 5, with volatility likely if the decision disappoints.
The FDA date is specific and time-bound, but the article does not provide a new FDA outcome or new Moderna filing beyond what is implied as known scheduling.
Article frames Viking Therapeutics’ dual GLP-1/GIP Phase 3 obesity program as binary, with oral VK2735 Phase 3 initiation scheduled for Q3 2026.
Potentially large upside if Phase 3 data supports differentiation, but sharp drawdowns if efficacy or tolerability disappoints.
The article provides trial enrollment and Phase 2 magnitude plus a scheduled Phase 3 start window, but it is still an outlook/basket piece rather than a new clinical readout.
Market effects
Reinforces a late-2026 biotech catalyst calendar narrative, potentially supporting momentum in obesity and vaccine-adjacent names.
Primarily US-listed biotech sentiment; could spill into broader US healthcare risk appetite.
Mentions international approvals/demand stabilization, but the actionable catalysts are US FDA and US-listed trial timelines.
Counterpoint
The article’s “massive upside” is largely scenario-based (analyst targets, binary Phase 3 framing) and may overstate near-term probability-weighted returns.
Key entities
- companyRegeneron
Anchors the basket with Q1 2026 financial beats, a $3.0B buyback authorization, and multiple late-2026 catalysts including an August 2026 garetosmab BLA action date.
- companyModerna
Positioned around an Aug. 5 FDA PDUFA decision for seasonal flu vaccine mRNA-1010, described as a near-term re-rating catalyst.
- companyViking Therapeutics
Framed as a high-risk obesity pipeline play, with dual GLP-1/GIP Phase 3 trials and a Q3 2026 oral VK2735 Phase 3 initiation window.
